Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dexamethasone + Ponatinib + Vincristine Sulfate |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Ponatinib | Iclusig | AP24534 | ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 29 DDR1 Inhibitor 9 DDR2 inhibitor 7 FGFR Inhibitor (Pan) 25 FLT3 Inhibitor 64 KIT Inhibitor 56 PDGFR-alpha Inhibitor 9 RET Inhibitor 52 SRC Inhibitor 31 VEGFR Inhibitor (Pan) 36 | Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748, PMID: 19878872). Iclusig (ponatinib) is FDA approved for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL) as well as ABL1 T315I CML and ABL1 T315I Ph positive ALL (FDA.gov). |
Vincristine Sulfate | Oncovin | 22-Oxovincaleukoblastine|vincristine | Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03589326 | Phase III | Cytarabine + Methotrexate + Ponatinib Dexamethasone + Ponatinib + Vincristine Sulfate Ponatinib + Prednisone + Vincristine Sulfate Dexamethasone + Imatinib + Vincristine Sulfate Cytarabine + Imatinib + Methotrexate Imatinib + Prednisone + Vincristine Sulfate | A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | Recruiting | USA | ITA | FRA | ESP | CAN | AUT | AUS | 13 |